Investigational^↗Rare disease^↗

Elamipretide^↗

Related names in cited records: SS-31, MTP-131^↗

A mitochondria-targeting peptide candidate. This profile cites a recruiting ClinicalTrials.gov study record.^↗

Citation markers ↗ open the public records supporting the adjacent statements.

Profile update · July 27, 2026

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change. ¹

This version supersedes public version 1.

Evidence summary

What the cited records say

ClinicalTrials.gov lists the 4TAZPower study as recruiting, updated July 13, 2026.^↗

This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

Cited context

Dated source history

July 13, 2026
Clinical trials
Elamipretide Barth syndrome study record updated^↗
ClinicalTrials.gov lists a recruiting Elamipretide study sponsored by Stealth BioTherapeutics Inc.^↗